olopatadine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
histamine-H1 receptor antagonists, tricyclic compounds	1986	113806-05-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: olopatadine olopatadine hydrochloride opatanol pataday patanol olopatadine HCl	An antihistamine with mast-cell stabilizing properties used as eye drops in the treatment of ALLERGIC CONJUNCTIVITIS. Molecular weight: 337.42 Formula: C21H23NO3 CLOGP: 1.09 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 49.77 ALOGS: -4.03 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

olopatadine
olopatadine hydrochloride
opatanol
pataday
patanol
olopatadine HCl

An antihistamine with mast-cell stabilizing properties used as eye drops in the treatment of ALLERGIC CONJUNCTIVITIS.

Molecular weight: 337.42
Formula: C21H23NO3
CLOGP: 1.09
LIPINSKI: 0
HAC: 4
HDO: 1
TPSA: 49.77
ALOGS: -4.03
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	28.04 mg/mL	Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine)	65 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.11 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

Date	Agency	Company	Orphan
Dec. 18, 1996	FDA	ALCON

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Treatment failure	1438.18	13.78	704	10894	198339	63279085
Eye irritation	114.63	13.78	63	11535	21908	63455516
Asthma	67.76	13.78	99	11499	127462	63349962
Eye pruritus	61.95	13.78	40	11558	18631	63458793
Sinusitis	51.52	13.78	122	11476	226531	63250893
Conjunctivitis allergic	47.76	13.78	14	11584	928	63476496
Urticarial vasculitis	47.61	13.78	13	11585	666	63476758
Ocular hyperaemia	38.69	13.78	34	11564	25110	63452314
Total cholesterol/HDL ratio abnormal	35.88	13.78	7	11591	77	63477347
Eye discharge	33.31	13.78	18	11580	6045	63471379
Dry eye	33.07	13.78	39	11559	40722	63436702
Toxicity to various agents	31.54	13.78	4	11594	247246	63230178
Eyelid margin crusting	29.53	13.78	10	11588	1062	63476362
Hepatic function abnormal	29.24	13.78	35	11563	37107	63440317
Upper respiratory tract inflammation	27.58	13.78	12	11586	2511	63474913
Drug intolerance	27.50	13.78	11	11587	308650	63168774
Maternal exposure during pregnancy	27.03	13.78	4	11594	220058	63257366
Systemic lupus erythematosus	25.19	13.78	4	11594	208914	63268510
Alopecia areata	25.12	13.78	10	11588	1675	63475749
Vision blurred	24.77	13.78	53	11545	91871	63385553
Product packaging quantity issue	23.57	13.78	9	11589	1350	63476074
Dermatitis atopic	23.18	13.78	17	11581	9707	63467717
Urticaria aquagenic	21.76	13.78	4	11594	31	63477393
Urticaria cholinergic	21.65	13.78	4	11594	32	63477392
Synovitis	21.61	13.78	4	11594	186914	63290510
Arthropathy	21.51	13.78	8	11590	234784	63242640
Infusion site swelling	20.89	13.78	16	11582	9754	63467670
Glossodynia	20.31	13.78	4	11594	178872	63298552
Lichenification	19.75	13.78	6	11592	450	63476974
Eye swelling	19.59	13.78	23	11575	23895	63453529
Adrenal insufficiency	19.49	13.78	20	11578	17895	63459529
Foreign body sensation in eyes	19.25	13.78	9	11589	2225	63475199
Bronchitis	18.97	13.78	58	11540	124877	63352547
Burning feet syndrome	18.77	13.78	4	11594	70	63477354
Hypohidrosis	18.77	13.78	4	11594	70	63477354
Infusion site pain	18.65	13.78	19	11579	16850	63460574
Infusion site erythema	18.38	13.78	16	11582	11663	63465761
Rheumatoid arthritis	18.20	13.78	12	11586	253807	63223617
Ear infection	17.89	13.78	28	11570	38185	63439239
Infusion site extravasation	17.87	13.78	15	11583	10411	63467013
Eye pain	17.54	13.78	26	11572	33828	63443596
Conjunctivitis	17.03	13.78	20	11578	20776	63456648
Eyelid infection	16.83	13.78	5	11593	347	63477077
Dry skin	16.72	13.78	34	11564	56853	63420571
Renal colic	16.05	13.78	7	11591	1474	63475950
Pulmonary mass	15.70	13.78	20	11578	22576	63454848
Eczema	15.59	13.78	24	11574	32267	63445157
Headache	15.44	13.78	180	11418	633061	62844363
Infusion site pruritus	15.41	13.78	11	11587	6024	63471400
Fulminant type 1 diabetes mellitus	15.36	13.78	5	11593	470	63476954
General physical health deterioration	15.15	13.78	9	11589	201393	63276031
Eye allergy	15.14	13.78	6	11592	993	63476431
Vein collapse	14.89	13.78	6	11592	1038	63476386
Drug eruption	14.81	13.78	22	11576	28672	63448752
Neutrophil count decreased	14.59	13.78	32	11566	56374	63421050
Rhinitis allergic	14.43	13.78	14	11584	11713	63465711
Off label use	14.33	13.78	69	11529	674393	62803031
Cholangitis	13.89	13.78	10	11588	5551	63471873

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Treatment failure	730.57	17.93	264	4543	46433	34905691
Eye irritation	68.64	17.93	29	4778	7532	34944592
Hypersensitivity	47.81	17.93	50	4757	60985	34891139
Ocular hyperaemia	43.00	17.93	24	4783	11428	34940696
Asthma	42.78	17.93	40	4767	42616	34909508
Hepatic function abnormal	34.10	17.93	36	4771	44327	34907797
Dermatitis atopic	34.04	17.93	16	4791	5331	34946793
Rash	32.70	17.93	85	4722	222667	34729457
Cerebral infarction	31.94	17.93	28	4779	27427	34924697
Alopecia areata	30.60	17.93	7	4800	231	34951893
Pruritus	30.53	17.93	63	4744	141918	34810206
Drug eruption	28.74	17.93	23	4784	19875	34932249
Interstitial lung disease	27.36	17.93	39	4768	65243	34886881
Sinusitis	27.30	17.93	31	4776	41371	34910753
Eye discharge	26.19	17.93	10	4797	1996	34950128
Dry eye	22.83	17.93	15	4792	9560	34942564
Product delivery mechanism issue	21.91	17.93	5	4802	163	34951961
Conjunctivitis allergic	19.58	17.93	7	4800	1163	34950961
Erythema multiforme	19.29	17.93	13	4794	8636	34943488
Eye pain	18.25	17.93	15	4792	13447	34938677

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Asthma	88.26	14.01	104	11632	134991	79597661
Hepatic function abnormal	62.80	14.01	65	11671	73042	79659610
Alopecia areata	49.52	14.01	16	11720	1827	79730825
Dermatitis atopic	47.18	14.01	25	11711	10031	79722621
Eye irritation	44.03	14.01	31	11705	20650	79712002
Drug eruption	41.25	14.01	41	11695	43894	79688758
Urticarial vasculitis	37.66	14.01	10	11726	574	79732078
Total cholesterol/HDL ratio abnormal	37.31	14.01	7	11729	78	79732574
Upper respiratory tract inflammation	37.30	14.01	16	11720	4019	79728633
Sinusitis	35.98	14.01	85	11651	195416	79537236
Ocular hyperaemia	35.51	14.01	31	11705	28175	79704477
Adrenal insufficiency	31.31	14.01	29	11707	28458	79704194
Interstitial lung disease	31.31	14.01	58	11678	112542	79620110
Platelet count decreased	30.92	14.01	80	11656	194584	79538068
Neutrophil count decreased	30.77	14.01	52	11684	93907	79638745
Conjunctivitis allergic	30.75	14.01	11	11725	1709	79730943
Cerebral infarction	29.50	14.01	35	11701	45641	79687011
Urticaria	26.26	14.01	73	11663	185128	79547524
Erythema multiforme	25.50	14.01	21	11715	17630	79715022
Pruritus	23.88	14.01	118	11618	394530	79338122
Drug intolerance	23.67	14.01	5	11731	264114	79468538
Eye pruritus	22.72	14.01	21	11715	20549	79712103
Urticaria aquagenic	22.63	14.01	4	11732	31	79732621
Urticaria cholinergic	22.51	14.01	4	11732	32	79732620
Dry eye	21.74	14.01	27	11709	36904	79695748
Pyrexia	21.59	14.01	172	11564	678537	79054115
Lichenification	21.44	14.01	7	11729	826	79731826
Completed suicide	21.32	14.01	5	11731	245762	79486890
Malaise	20.70	14.01	133	11603	489736	79242916
Erythema	20.66	14.01	76	11660	223214	79509438
Bronchitis	20.02	14.01	53	11683	130591	79602061
Off label use	19.82	14.01	68	11668	907147	78825505
Hypohidrosis	18.74	14.01	5	11731	292	79732360
Rash	18.06	14.01	146	11590	578212	79154440
Concomitant disease aggravated	17.64	14.01	15	11721	13152	79719500
Eye discharge	17.58	14.01	11	11725	6023	79726629
Eyelid infection	17.41	14.01	5	11731	384	79732268
Eye pain	16.77	14.01	24	11712	37554	79695098
Eczema	16.67	14.01	25	11711	40793	79691859
Rhinitis allergic	16.49	14.01	14	11722	12255	79720397
Cardiac disorder	15.97	14.01	32	11704	65725	79666927
Headache	15.76	14.01	156	11580	653616	79079036
Vein collapse	15.69	14.01	6	11730	1122	79731530
Syphilis	15.66	14.01	5	11731	549	79732103
Burning feet syndrome	15.60	14.01	4	11732	200	79732452
Myofascial pain syndrome	15.36	14.01	7	11729	2030	79730622
Anaphylactic reaction	14.94	14.01	36	11700	83707	79648945
Fulminant type 1 diabetes mellitus	14.10	14.01	6	11730	1477	79731175
Alopecia universalis	14.10	14.01	4	11732	294	79732358
Dry skin	14.08	14.01	31	11705	67964	79664688
Contraindicated product administered	14.07	14.01	3	11733	157535	79575117
Cholangitis	14.02	14.01	13	11723	12763	79719889

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	R01AC08	RESPIRATORY SYSTEM NASAL PREPARATIONS DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE Antiallergic agents, excl. corticosteroids
ATC	S01GX09	SENSORY ORGANS OPHTHALMOLOGICALS DECONGESTANTS AND ANTIALLERGICS Other antiallergics
FDA MoA	N0000000190	Histamine H1 Receptor Antagonists
FDA EPC	N0000175519	Histamine-1 Receptor Inhibitor
FDA EPC	N0000175587	Histamine-1 Receptor Antagonist
MeSH PA	D000700	Analgesics
MeSH PA	D018712	Analgesics, Non-Narcotic
MeSH PA	D018926	Anti-Allergic Agents
MeSH PA	D000893	Anti-Inflammatory Agents
MeSH PA	D000894	Anti-Inflammatory Agents, Non-Steroidal
MeSH PA	D018501	Antirheumatic Agents
MeSH PA	D018494	Histamine Agents
MeSH PA	D006633	Histamine Antagonists
MeSH PA	D006634	Histamine H1 Antagonists
MeSH PA	D039563	Histamine H1 Antagonists, Non-Sedating
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D018689	Sensory System Agents
FDA PE	N0000175628	Decreased Histamine Release
FDA EPC	N0000175630	Mast Cell Stabilizer

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Allergic rhinitis	indication	61582004
Seasonal allergic rhinitis	indication	367498001
Allergic conjunctivitis	indication	473460002	DOID:11204
Epistaxis	contraindication	12441001
Perforation of nasal septum	contraindication	80142000
Nasal Lesions	contraindication
Nasal Septal Ulcers	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.89	acidic
pKa2	8.66	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 0.7% BASE	PATADAY ONCE DAILY RELIEF	ALCON LABS INC	N206276	Jan. 30, 2015	OTC	SOLUTION/DROPS	OPHTHALMIC	8791154	May 19, 2032	TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS
0.025MG/SPRAY;0.665MG/SPRAY	RYALTRIS	GLENMARK SPECIALTY	N211746	Jan. 13, 2022	RX	SPRAY, METERED	NASAL	10016443	Sept. 4, 2034	TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE
0.025MG/SPRAY;0.665MG/SPRAY	RYALTRIS	GLENMARK SPECIALTY	N211746	Jan. 13, 2022	RX	SPRAY, METERED	NASAL	10517880	Sept. 4, 2034	TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE
0.025MG/SPRAY;0.665MG/SPRAY	RYALTRIS	GLENMARK SPECIALTY	N211746	Jan. 13, 2022	RX	SPRAY, METERED	NASAL	10548907	Sept. 4, 2034	TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE
0.025MG/SPRAY;0.665MG/SPRAY	RYALTRIS	GLENMARK SPECIALTY	N211746	Jan. 13, 2022	RX	SPRAY, METERED	NASAL	10646500	Sept. 4, 2034	TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE
0.025MG/SPRAY;0.665MG/SPRAY	RYALTRIS	GLENMARK SPECIALTY	N211746	Jan. 13, 2022	RX	SPRAY, METERED	NASAL	10758550	Sept. 4, 2034	TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE TO A PEDIATRIC PATIENT
0.025MG/SPRAY;0.665MG/SPRAY	RYALTRIS	GLENMARK SPECIALTY	N211746	Jan. 13, 2022	RX	SPRAY, METERED	NASAL	10765686	Sept. 4, 2034	METHOD OF DELIVERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE TO A NASAL AIRWAY
0.025MG/SPRAY;0.665MG/SPRAY	RYALTRIS	GLENMARK SPECIALTY	N211746	Jan. 13, 2022	RX	SPRAY, METERED	NASAL	11400101	Sept. 4, 2034	TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE
0.025MG/SPRAY;0.665MG/SPRAY	RYALTRIS	GLENMARK SPECIALTY	N211746	Jan. 13, 2022	RX	SPRAY, METERED	NASAL	9078923	Sept. 4, 2034	TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE
0.025MG/SPRAY;0.665MG/SPRAY	RYALTRIS	GLENMARK SPECIALTY	N211746	Jan. 13, 2022	RX	SPRAY, METERED	NASAL	9750754	Sept. 4, 2034	TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
0.025MG/SPRAY;0.665MG/SPRAY	RYALTRIS	GLENMARK SPECIALTY	N211746	Jan. 13, 2022	RX	SPRAY, METERED	NASAL	Jan. 13, 2025	NEW PRODUCT

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN	ANTAGONIST	Ki	8.28		WOMBAT-PK	CHEMBL
Histamine H1 receptor	GPCR		HRH1_CAVPO		Ki	7.80		CHEMBL

External reference:

ID	Source
4021024	VUID
N0000148491	NUI
D01192	KEGG_DRUG
140462-76-6	SECONDARY_CAS_RN
4021024	VANDF
4021040	VANDF
C0527189	UMLSCUI
CHEBI:7769	CHEBI
CHEMBL1189432	ChEMBL_ID
DB00768	DRUGBANK_ID
CHEMBL1719	ChEMBL_ID
D000069605	MESH_DESCRIPTOR_UI
5281071	PUBCHEM_CID
7249	IUPHAR_LIGAND_ID
7257	INN_ID
D27V6190PM	UNII
135391	RXNORM
10342	MMSL
107496	MMSL
230004	MMSL
5199	MMSL
006403	NDDF
006404	NDDF
108843008	SNOMEDCT_US
108845001	SNOMEDCT_US
372550002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
PATANASE	HUMAN PRESCRIPTION DRUG LABEL	1	0065-0332	SPRAY, METERED	600 ug	NASAL	NDA	29 sections
PATANASE	HUMAN PRESCRIPTION DRUG LABEL	1	0065-0332	SPRAY, METERED	600 ug	NASAL	NDA	29 sections
PATADAY ONCE DAILY RELIEF	HUMAN OTC DRUG LABEL	1	0065-0816	SOLUTION	7 mg	OPHTHALMIC	NDA	12 sections
PATADAY ONCE DAILY RELIEF	HUMAN OTC DRUG LABEL	1	0065-0816	SOLUTION	7 mg	OPHTHALMIC	NDA	12 sections
Pazeo	HUMAN PRESCRIPTION DRUG LABEL	1	0065-4273	SOLUTION	7 mg	OPHTHALMIC	NDA	22 sections
PATADAY TWICE A DAY RELIEF	HUMAN OTC DRUG LABEL	1	0065-4274	SOLUTION	1 mg	OPHTHALMIC	NDA	12 sections
PATADAY TWICE A DAY RELIEF	HUMAN OTC DRUG LABEL	1	0065-4274	SOLUTION	1 mg	OPHTHALMIC	NDA	12 sections
PATADAY ONCE DAILY RELIEF	HUMAN OTC DRUG LABEL	1	0065-8150	SOLUTION	2 mg	OPHTHALMIC	NDA	12 sections
PATADAY ONCE DAILY RELIEF	HUMAN OTC DRUG LABEL	1	0065-8150	SOLUTION	2 mg	OPHTHALMIC	NDA	12 sections
PATANASE	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0834	SPRAY, METERED	600 ug	NASAL	NDA	29 sections
PATANASE	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0834	SPRAY, METERED	600 ug	NASAL	NDA	29 sections
Olopatadine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7684	SOLUTION/ DROPS	2 mg	OPHTHALMIC	ANDA	22 sections
Olopatadine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7684	SOLUTION/ DROPS	2 mg	OPHTHALMIC	ANDA	22 sections
OLOPATADINE HYDROCHLORIDE	Human OTC Drug Label	1	0363-0200	SOLUTION	1 mg	OPHTHALMIC	ANDA	13 sections
Olopatadine Hydrochloride Ophthalmic Solution	Human OTC Drug Label	1	0363-7130	SOLUTION/ DROPS	1 mg	OPHTHALMIC	ANDA	13 sections
Olopatadine Hydrochloride Ophthalmic Solution	Human OTC Drug Label	1	0363-7131	SOLUTION	2 mg	OPHTHALMIC	ANDA	11 sections
OLOPATADINE HYDROCHLORIDE	Human OTC Drug Label	1	0363-8022	SOLUTION	2 mg	OPHTHALMIC	ANDA	13 sections
Olopatadine Hydrochloride Ophthalmic Solution	Human OTC Drug Label	1	0536-1307	SOLUTION	2 mg	OPHTHALMIC	ANDA	11 sections
Olopatadine Hydrochloride Ophthalmic Solution	Human OTC Drug Label	1	0536-1307	SOLUTION	2 mg	OPHTHALMIC	ANDA	11 sections
Olopatadine Hydrochloride Ophthalmic Solution	Human OTC Drug Label	1	0536-1308	SOLUTION/ DROPS	1 mg	OPHTHALMIC	ANDA	13 sections
Olopatadine Hydrochloride Ophthalmic Solution	Human OTC Drug Label	1	0536-1308	SOLUTION/ DROPS	1 mg	OPHTHALMIC	ANDA	13 sections
Olopatadine Hydrochloride Ophthalmic Solution	Human OTC Drug Label	1	11673-688	SOLUTION	2 mg	OPHTHALMIC	ANDA	11 sections
Olopatadine Hydrochloride Ophthalmic Solution	Human OTC Drug Label	1	11673-689	SOLUTION/ DROPS	1 mg	OPHTHALMIC	ANDA	13 sections
Olopatadine Hydrochloride Ophthalmic Solution	Human OTC Drug Label	1	11822-9975	SOLUTION	2 mg	OPHTHALMIC	ANDA	11 sections
Olopatadine Hydrochloride Ophthalmic Solution	Human OTC Drug Label	1	11822-9976	SOLUTION/ DROPS	1 mg	OPHTHALMIC	ANDA	13 sections
Olopatadine	HUMAN PRESCRIPTION DRUG LABEL	1	17478-105	SOLUTION/ DROPS	1 mg	OPHTHALMIC	ANDA	17 sections
Olopatadine	HUMAN PRESCRIPTION DRUG LABEL	1	17478-305	SOLUTION/ DROPS	2 mg	OPHTHALMIC	ANDA	24 sections
Olopatadine	HUMAN PRESCRIPTION DRUG LABEL	1	17478-305	SOLUTION/ DROPS	2 mg	OPHTHALMIC	ANDA	24 sections
Olopatadine	HUMAN OTC DRUG LABEL	1	17478-308	SOLUTION/ DROPS	1 mg	OPHTHALMIC	ANDA	13 sections
Olopatadine	HUMAN OTC DRUG LABEL	1	17478-312	SOLUTION/ DROPS	2 mg	OPHTHALMIC	ANDA	13 sections